Check for updates

OPEN ACCESS

EDITED BY Csaba Balázs, Buda Health Center, Hungary

REVIEWED BY Ilker Sengul, Giresun University, Türkiye Yu Lan, China Medical University, China Flavio Hojaij, University of São Paulo, Brazil

*CORRESPONDENCE Shuangquan Jiang 23237003@qq.com

RECEIVED 30 January 2025 ACCEPTED 23 June 2025 PUBLISHED 18 July 2025

CITATION

Mei X, Fu Q, Li G, Ai X, Sun Y, Tian J, Leng X and Jiang S (2025) Clinical study on the impact of microwave ablation energy on the treatment efficacy of benign thyroid nodules. *Front. Oncol.* 15:1568697. doi: 10.3389/fonc.2025.1568697

COPYRIGHT

© 2025 Mei, Fu, Li, Ai, Sun, Tian, Leng and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Clinical study on the impact of microwave ablation energy on the treatment efficacy of benign thyroid nodules

Xue Mei^{1,2}, Qianqian Fu³, Guangyin Li¹, Xin Ai¹, Yu Sun⁴, Jiawei Tian¹, Xiaoping Leng¹ and Shuangquan Jiang^{1*}

¹Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, ²Department of Ultrasound Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China, ³Daqing People's Hospital, Ultrasound Room, Daqing, Heilongjiang, China, ⁴Department of Thyroid Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China

Objective: We aimed to establish a model to estimate the energy required for microwave ablation (MWA) to achieve the desired effect and analyze the factors influencing its therapeutic efficacy.

Materials and Methods: We retrospectively analyzed 117 patients with benign thyroid nodules. A quadratic regression model was established to analyze the relationship between the technical parameters of MWA and volume reduction rate (VRR). Both univariate and multivariate logistic regression analyses were used to identify factors influencing the efficacy of MWA treatment.

Results: The volume of nodules continued to decrease at 1, 3, 6, and 12 months after ablation, and the mean of VRR was 77.5 \pm 15.9% at 12 months after ablation. Among these nodules, 72 (61.5%) had a VRR \geq 75%, whereas 45 (38.5%) had a VRR < 75%. The energy volume ratio was significantly correlated with the VRR. When the VRR \geq 75%, the energy volume ratio ranges 784-2,274 J/mL. Among all parameters, only the energy volume ratio and calcification were independent factors influencing the treatment efficacy for benign thyroid nodules (*P* < 0.05).

Conclusions: The efficacy of the treatment was optimized when the energy volume ratio of the MWA fell within a certain range. The energy volume ratio and calcification are related to the efficacy of MWA treatment.

KEYWORDS

thyroid nodule, ablation techniques, microwaves, energy transfer, ultrasonography

1 Introduction

The proportion of benign thyroid nodules is 80-95%, and clinical intervention is required when the nodules are large, have local compression symptoms, or affect appearance (1). Thermal ablation has recently become a new treatment option for thyroid nodules. Ultrasound-guided thermal ablation has the advantages of less trauma, faster recovery, high safety, and no influence on thyroid function. Several guidelines recommend it as an alternative to surgical treatment or regular observation (2, 3). Numerous studies have revealed that thermal ablation has favorable effects on benign thyroid nodules (4-6). Liu et al. used microwave ablation (MWA) to treat 173 cases of benign thyroid nodules, and the volume reduction ratio (VRR) of the nodules reached 89% 1 year after treatment (7). Cappelli et al. used radiofrequency ablation (RFA) to treat functional and nonfunctional thyroid nodules, and the average VRR of nodules was $69.1 \pm 17.3\%$ at 1 year after treatment (8). Cesareo et al. compared the efficacy of RFA and laser ablation (LA) in the treatment of benign thyroid nodules, and the VRR was 70.9 \pm 16.9% and 60.0 \pm 19.0% 1 year after treatment, respectively (9).

There are significant differences in the therapeutic efficacy of different study populations and thermal ablation treatment methods. In recent years, a few researchers have attempted to explore the influencing factors of the efficacy of thermal ablation therapy. Deandrea et al. revealed that nodule composition, initial volume, and blood flow distribution are related to postoperative efficacy (10). Fu et al. revealed that the internal components of the nodules, enhancement pattern, and immediate postoperative volume were independent factors that influenced the curative effect (11). Li et al. showed that the VRR of nodules in a group with coarse calcifications was lower (12). Numerous studies have been conducted on the effects of nodule characteristics on the efficacy of ablation (13-15). In addition, the influence of technical parameters of thermal ablation on its effectiveness has also been reported. Trimboli et al. discussed the technical parameters related to RFA in the treatment of benign thyroid nodules, and their results revealed that the energy volume ratio was significantly correlated with the VRR (16). Gambelunghe et al. evaluated the effect of the energy volume ratio on the efficacy of LA in the treatment of benign thyroid nodules and found that the treatment was effective only when the energy volume ratio was > 400-500 J/mL (17). Amabile et al. found that lower LA energy significantly reduced the volume of benign thyroid nodules (18). At present, research on the influence of the technical parameters of thermal ablation on the therapeutic effects mostly focuses on LA and RFA. However, a few studies report on the effects of the technical parameters of MWA on therapeutic efficacy. Because the working principle of MWA is different from that of LA and RFA, the results may also be different. Therefore, we aimed to explore the parameters that affect the therapeutic effects of MWA.

2 Materials and methods

2.1 Participants

We retrospectively analyzed 307 patients treated with ultrasound-guided MWA at our hospital between September 2021 and December 2023. Of these, 190 were excluded due to loss to follow-up or incomplete data during follow-up, and 117 patients, including 10 males and 107 females, were included. The inclusion criteria were as follows: (1) fine needle aspiration or core needle biopsy confirmed that the nodule was benign; (2) unilateral single solid nodule with a maximum diameter of ≥ 2 cm and increasing gradually (19); (3) presence of symptoms such as neck compression, foreign body sensation, or patients actively requesting treatment due to anxiety. The exclusion criteria were as follows: (1) previous thyroid surgery or ablation therapy; (2) severe heart and lung disease or coagulation dysfunction; and (3) incomplete clinical, ultrasound, and pathological data. This study was approved by the Academy Ethics Committee (Ethics Number: YJSKY2022-399).

2.2 Evaluation prior to MWA

An Aixplorer ultrasound system (SuperSonic Image. SA, France) equipped with an L15–4 high-frequency linear probe (4– 15MHz) and L10–2 high-frequency linear probe (2–10MHz) was used for the evaluation and ablation treatment guidance of nodules. The ablation instrument used was the KY2000 microwave ablation therapy instrument (Nanjing Kangyou Medical Technology Company Limited) equipped with a 16G sterile disposable microwave ablation needle.

The size, echo, calcification, and blood flow distribution of the nodules were evaluated using ultrasonography before MWA. According to the diameter of the three dimensions of the nodule, the nodule volume was calculated in the following manner: $V = a \times b \times c \times \Pi/6$ (V: volume, a: upper and lower diameter, b: left and right diameter, c: anterior and posterior diameter). The patient underwent electrocardiography, laryngoscopy and laboratory tests before ablation. Before treatment, patients and their families signed an informed consent form.

2.3 MWA treatment process and technical parameters

MWA was performed after a fine preoperative evaluation. Vital signs including blood pressure, heart rate, and blood oxygen levels were continuously monitored during the operation. The surgical area was disinfected, the hole towel was spread, the optimal puncture site was determined under ultrasound guidance in real time, and 5 mL of 2% lidocaine was injected subcutaneously for local infiltration anesthesia. Further, 20–40 mL of normal saline and lidocaine mixed liquid (18:2) is injected between the thyroid gland and adjacent important tissues (such as common carotid artery, recurrent laryngeal nerve, trachea, esophagus, etc.) to provide an

Abbreviations: MWA, Microwave ablation; VRR, Volume reduction rate; RFA, Radiofrequency ablation; LA, Laser ablation.

"isolation zone" for ablation treatment and avoid damage to surrounding tissues. According to the specific location of the nodule, a translateral cervical or transisthmus approach was used, and moving-shot technique was used to ablate the target nodule layer-by-layer. The ablation needle was withdrawn when the target nodule was completely covered by the strong-echo gasification zone and CDFI showed no blood flow signal within the nodule. Contrastenhanced ultrasound examination was performed immediately after the pneumatization subsided to evaluate whether the ablation treatment was complete, and additional ablation was performed on the area with residual contrast agent perfusion inside the nodule. During the ablation process, the patient's feelings were intermittently investigated, and whether the patient experienced thermal damage to the recurrent laryngeal nerve was assessed based on vocalization. The mobility of the false vocal cords was also evaluated using ultrasonography. After the ablation treatment was completed, cold compression was applied to the ablation area for 1 h to stop bleeding and reduce pain. Patients were observed for 4 h after the operation, and the occurrence of complications was recorded in detail. All patients were treated by the same surgeon with > 8 years of ablation experience.

The output power of the microwave ablation instrument was set to 30 W, the duration of MWA treatment was recorded, and the total ablation energy was expressed in joules (total ablation energy = ablation time \times ablation power). The energy volume ratio was calculated using the following formula: energy volume ratio = total ablation energy/nodule volume.

2.4 Postoperative follow-up

Thyroid ultrasound examination was performed 1, 3, 6, and 12 months after ablation to observe blood perfusion in the nodules. The VRR of the nodule was calculated as follows: VRR = (baseline volume – final volume)/baseline volume × 100%. With 12 months after ablation as the observation endpoint, the patients were classified into the significantly effective group (VRR \geq 75%) and the nonsignificantly effective group (VRR < 75%) based on whether the VRR exceeded 75%.

2.5 Statistical analysis

SPSS26.0 software was used for data analysis. A quadratic regression model was used to analyze the relationship between the technical parameters of the MWA treatment and the VRR. Count data were expressed in rate (%), and χ^2 test was used for comparison between groups. The normality test was performed for the continuous data, and those who conformed to the normal distribution were expressed by the mean \pm standard deviation, and the independent samples t-test was used for comparison between groups. Continuous data that did not conform to a normal distribution were expressed as medians and upper and lower quartiles, and rank-sum tests were used for comparisons

between the groups. Statistically significant factors in the univariate analysis were included in the binary logistic regression analysis. P < 0.05 was considered statistically significant.

3 Results

All 117 patients completed postoperative follow-up at each time point, and the nodule volume gradually decreased (Figure 1). None of the patients experienced tumor recurrence or regeneration. At 12 months after the operation, the mean VRR of nodules was 77.5 \pm 15.9% (29.1%-98.6%). Among them, 72 cases (61.5%) had a VRR \geq 75%, and 45 cases (38.5%) had a VRR < 75%. Eight patients (6.8%) experienced side effects after ablation, including seven cases of neck pain and one case of fever. The symptoms disappeared within 1 day to 1 week of ablation without treatment. Two patients (1.7%) experienced minor complications of hoarseness, which returned to normal during the follow-up examination 1 month after treatment.

3.1 Changes in the thyroid nodule volume after MWA treatment

The mean volume of thyroid nodules was (13.47 ± 9.72) mL before MWA, and the volume of thyroid nodules continued to shrink at 1, 3, 6, and 12 months after operation, which were 9.66 ± 7.94, 7.08 ± 5.89, 5.37 ± 5.07, 3.49 ± 4.65 mL, respectively (Figure 2). The average VRRs increased gradually at 1, 3, 6, and 12 months after operation, which were 28.9 ± 18.4%, 47.0 ± 16.9%, 61.2 ± 16.0%, 77.5 ± 15.9%, respectively.

The VRR of the two groups at different time points after the operation were compared using a repeated-measures analysis of variance. The results showed significant differences in the VRR between the two groups at different observation time points (F = 455.48, P < 0.01). In addition, at the same observation time point, the difference in VRR between the two groups was statistically significant (F = 69.91, P < 0.01). (Table 1, Figure 3).

3.2 Relationship between technical parameters and efficacy of MWA treatment

A quadratic regression model was established to analyze the relationship between the ablation time, total energy, energy volume ratio, and VRR. The results revealed that only the energy volume ratio was significantly correlated with VRR at 12 months after ablation (P < 0.001), and the ablation time and total ablation energy were not related to VRR (P = 0.766 and P = 0.859). According to the fitting curve of the established model, the energy volume ratio was between 784 J/mL and 2274 J/mL, when the VRR \geq 75% (Figure 4).

The collinearity between the energy volume ratio, total energy, and nodule volume was analyzed. The results showed that the energy volume ratio and total energy were related to the nodule volume (both P < 0.001) (Figure 5).



FIGURE 1

The patient is a 49-year-old female. (A, B) Preoperative ultrasound reveals large nodules in the thyroid isthmus and left lobe, which are isoechoic, with clear borders, Adler blood flow grade III, no calcification, size 3.92 cm × 2.05 cm × 4.04 cm, and volume 16.9 mL; (C) Two-dimensional ultrasound immediately after MWA reveals an oval-shaped hypoechoic state with clear boundaries; (D) Contrast-enhanced ultrasound examination immediately after MWA reveals no perfusion within the nodule; (E-H) Two-dimensional ultrasound images obtained at 1, 3, 6, and 12 months after treatment, respectively. The lesion volume seems to have decreased gradually, and VRR is 78.5% at 12 months after ablation. MWA, microwave ablation; VRR, volume reduction rate.

3.3 Influencing factors of MWA treatment efficacy

Univariate analysis was performed on general clinical data, ultrasound characteristics, and technical parameters related to MWA treatment. The results revealed significant differences in nodule volume, echo, calcification, and energy volume ratio between the two groups (all P < 0.05) (Table 2). Multivariate logistic regression analysis was performed on the four statistically significant variables, and the results revealed that calcification and energy volume ratio were independent influencing factors for the treatment efficacy of benign thyroid nodules (all P < 0.05) (Table 3).

4 Discussion

The incidence of thyroid nodules is increasing year by year, with a detection rate of 65% in the population (20). Most benign thyroid nodules required follow-up. Large thyroid nodules can cause varying degrees of dyspnea or swallowing discomfort and require aggressive management. In 2000, LA was first applied for the palliative treatment of recurrent thyroid cancer, leading to an era of minimally invasive thermal ablation therapy for thyroid nodules (21). In 2006, Kim applied RFA to the ablation treatment of benign thyroid nodules, thereby confirming the feasibility of RFA for the treatment of benign thyroid nodules (22). In 2012, Feng performed



MWA treatment for 11 benign thyroid nodules for the first time, and the VRR was 45.99 \pm 29.90% at 12 months after treatment and the related symptoms were found to be improved (23). Over the last 20 years, patients and clinicians have gradually recognized the need for ultrasound-guided thermal ablation therapy. Compared with lasers and radiofrequency, MWA has the advantages of fast heating and a large ablation range and is more suitable for the treatment of larger nodules. In this study, 117 patients with benign thyroid nodules were treated with ultrasound-guided MWA. The characteristics of the nodules were evaluated by two-dimensional ultrasound before MWA. Elastography was used to assist in determining the benign or malignant nature of the nodules (24-26). Additionally, a fineneedle aspiration biopsy or core needle aspiration was performed to confirm the nature of the nodules. The results revealed that with the extension of the follow-up time, the volume of thyroid nodules gradually decreased, and the VRR gradually increased. Twelve months after ablation, 109 patients (93.2%) had a VRR \geq 50%, 72 patients (61.5%) had a VRR \geq 75%, and 29 patients (24.8%) had a VRR \ge 90%. After treatment, a small number of patients experienced side effects, such as neck pain and fever, and the symptoms disappeared quickly. Only two patients (1.7%) had mild complications of hoarseness, which recovered during the follow-up examination 1 month after ablation. Postoperative laryngoscopy was performed to determine whether vocal cord movement was normal. The results showed that MWA treatment of benign thyroid nodules was safe and effective.

Univariate analysis revealed a statistically significant difference in nodule size between the two groups. This study was based on whether the nodule volume was ≥ 20 mL. The results showed that smaller nodules had a higher VRR. This is consistent with the results of Dobnig et al. (27), who conducted a retrospective analysis of 154 benign thyroid nodules treated with RFA that revealed a VRR

of 82 \pm 13% at 12 months postoperatively. According to the initial nodule volume, the VRR was higher in patients with smaller initial volumes. Previous studies also concluded that the VRR of small nodules was more significant after MWA treatment (11), which may be because the larger the nodules, the more necrotic the tissue after ablation, and the longer it takes for the body to phagocytose and clear (28). Nodule echo can also affect the therapeutic effect of MWA, and (extremely) low-echo nodule VRR was higher than that of nonlow-echo VRR, and the therapeutic effect was more significant. This is consistent with previous studies, and Cao explored the independent influencing factors of the VRR after thermal ablation of benign thyroid nodules, which also revealed that low-echo nodules had a higher VRR (29). Kim et al. concluded that low-echo thyroid nodules contain more cells and fibrous tissue (30). The absorption of the ablation area is mainly dependent on the immune response caused by cell necrosis after thermal ablation. In low-echo nodules, more cells were absorbed more easily.

Furthermore, a statistically significant difference was observed in calcification between the two groups, and the results of multivariate logistic regression analysis revealed that calcification was an independent influencing factor affecting the efficacy of MWA treatment for benign thyroid nodules. At 12 months after ablation, noncalcified nodules were more effective than those with calcification, with VRR \geq 75% in 70.4% of noncalcified nodules and 15.8% of those with calcification. This is consistent with the findings of He et al. (31), who retrospectively analyzed 204 cases of papillary thyroid carcinoma treated with RFA and constructed a nomogram to predict whether the ablation area could be fully absorbed. These results reveal that calcification is closely related to whether the ablation area is fully absorbed. This may be due to the fact that the calcification impairs the conduction of heat energy and impairs the body's absorption of the ablation area.

TABLE 1 Comparison of VRR of nodules at various follow-up time points after operation.

	1 month	3 months	6 months	12 months
VRR ≥ 75% (%)	32.24 ± 18.56	53.03 ± 15.32	69.09 ± 12.71	87.88 ± 6.02
VRR < 75% (%)	23.64 ± 17.06	37.46 ± 15.02	48.56 ± 12.23	60.94 ± 12.40



In addition to the influence of nodule characteristics on the curative effect, we conducted an in-depth analysis of the influence of MWA technical parameters on the curative effect. Currently, there are few reports on the relationship between the technical parameters of thermal ablation and its therapeutic effect. Gambelunghe et al. (17) evaluated the technical parameters of the therapeutic effect of LA on benign thyroid nodules and found that treatment was effective only when the energy volume ratio was > 400–500 J/mL. Deandrea et al. (32) conducted a regression analysis on the energy required by RFA for the treatment of benign thyroid

nodules and found that when the nodules were administered 756 J/ mL, the treatment was effective with a 50% probability, and when the nodules were administered 2670 J/mL, the treatment was effective with a 99% probability. However, there are a few studies on the effect of MWA energy on the efficacy of treatment, and the results are not consistent. Korkusuz et al. (33) studied the energy required by MWA to treat symptomatic benign thyroid nodules, and their results revealed that the energy delivered by ablation was positively correlated with volume reduction. Cao et al. (29) showed that the VRR \geq 75% group required a lower energy volume ratio



FIGURE 4

Correlation among the ablation time, total ablation energy, energy volume ratio, and VRR at 12 months after ablation. VRR, volume reduction rate. P<0.001 was considered statistically significant. R square represents the proportion of the variance for a dependent variable that's explained by the independent variables in the regression model.



than the VRR < 75% group, based on whether the VRR was \ge 75% after MWA.

This study explored the relationship between the MWA time, total energy, energy volume ratio, and VRR. Through the establishment of a quadratic regression model, the results revealed that only the energy volume ratio was correlated with the VRR, and the fitting curve was parabolic. According to the fitting curve of the established model, when the energy volume ratio was between 784 and 2274 J/mL, the curative effect was found to be better; thus, the VRR could achieve more ideal results. The ablation time and total ablation energy were not related to the VRR. Multivariate logistic regression analysis also confirmed that the energy volume ratio was an independent factor affecting the VRR. The different results obtained using different thermal ablation methods may be related to their different working principles. MWA transmits electromagnetic energy through the antenna; polar water molecules rotate and function at a high speed under the action of the electric field, and friction generates heat, which, in turn, increases the temperature of the tissue, leading to coagulation necrosis of tumor tissues in the target area, thereby resulting in in-situ inactivation of the tumor. Subsequently, necrotic tissue is engulfed by macrophages and the tumor constantly shrinks and disappears (34). Therefore, in the process of ablation therapy, if the energy volume ratio is insufficient, tissue cell inactivation will be incomplete; if the ablation time is too long, the temperature of the tissue center will be too high and carbonization will occur, thereby resulting in postoperative malabsorption. This may explain why the relationship between the energy volume ratio and VRR is parabolic. The energy volume ratio is negatively correlated with nodule volume, which may be related to the moving-shot technique adopted for thyroid nodules. During the ablation process of large nodules, high heat is maintained continuously when the microwave antenna retreats. This can relatively reduce the frequency of microwave antenna reboots. RFA differs from MWA in that the radiofrequency ablation instrument reads the real-time impedance directly related to tissue coagulation and necrosis; the longer the tissue coagulation time, the higher the impedance (35). When the impedance was increased to a certain level, the RFA generator did not transmit energy, thereby avoiding tissue carbonization. LA transmits photon energy to the optical fiber to generate heat and make the tissue coagulate necrosis to achieve the purpose of killing the tumor (36). Additionally, LA has the advantage of accurate positioning. However, its therapeutic power is low and the ablation range of a single needle is small; therefore, the treatment is effective only when the energy of the LA for treating benign thyroid nodules attains sufficient energy levels.

This study obtained technical parameters related to the efficacy of MWA by establishing a model. In addition, the energy required

Factors	VRR <u>></u> 75% (n 72)	VRR < 75% (n 45)	$\chi^2/t/Z$	<i>P</i> value
Gender			0.011	0.917
Male	6 (60.0%)	4 (40.0%)		
Female	66 (61.7%)	41 (38.3%)		
Age(years)	43.93 ± 12.27	43.98 ± 13.13	0.020	0.984
Maximum diameter(cm)	3.75 ± 0.73	4.05 ± 0.94	1.904	0.059
Nodule volume			10.371	0.001
≥ 20mL	10 (35.7%)	18 (64.3%)		
< 20mL	62 (69.7%)	27 (30.3%)		
Echo			5.265	0.022
(Extreme) low echo	46 (70.8%)	19 (29.2%)		
Non-low echo	26 (50.0%)	26 (50.0%)		
Calcification			_	<0.001*
No	69 (70.4%)	29 (29.6%)		
Yes	3 (15.8%)	16 (84.2%)		
Adler blood flow grading			1.483	0.686
Level 0	3 (75.0%)	1 (25.0%)		
Level I	12 (52.2%)	11 (47.8%)		
Level II	27 (65.9%)	14 (34.1%)		
Level III	30 (61.2%)	19 (38.8%)		
Ablation time(s)	478.0 (370.0-701.0)	437.0 (259.5–599.5)	-0.647	0.518
Total energy(J)	14340.0 (11100.0-21030.0)	13920.0 (7785.0–19597.5)	-0.913	0.361
Energy volume ratio			_	<0.001*
784-2274J/mL	65 (77.4%)	19 (22.6%)		
<784J/mL or >2274J/mL	7 (21.2%)	26 (78.8%)		

TABLE 2 Analysis of influencing factors for the efficacy of benign thyroid nodules.

*Fisher exact probability method was used.

TABLE 3 Multivariate logistic regression analysis affecting the efficacy of benign thyroid nodules.

Factors	β	SE	Wald	Р	OR	95%Cl
Nodule volume	-0.685	0.559	1.501	0.221	0.504	0.169, 1.508
Echo	-0.270	0.480	0.316	0.574	0.764	0.298, 1.956
Calcification	1.649	0.742	4.934	0.026	5.201	1.214, 22.280
Energy volume ratio	1.972	0.540	13.332	<0.001	7.184	2.493, 20.704

to achieve good results was obtained. However, this study has several limitations. First, this was a retrospective study, and there may have been some bias in the results. In addition, because of the large number of patients lost to follow-up, approximately 61.9% of the initially enrolled patients were eventually excluded from the study, thereby resulting in a slightly small sample size, which may have affected the reliability of the study results. Furthermore, the follow-up period in this study was relatively short, and the results after long-term follow-up are worth investigating. This is a direction for future research.

5 Conclusion

In conclusion, MWA is safe and effective for the treatment of benign thyroid nodules, with no major complications occurred.

Energy volume ratio and calcification were independent factors that influenced the therapeutic effects of MWA. When the energy volume ratio of MWA is within a certain range, a better therapeutic effect can be achieved.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethics Committee of the Second Affiliated Hospital of Harbin Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

XM: Investigation, Writing – original draft. QF: Investigation, Writing – original draft. GL: Formal analysis, Writing – original draft. XA: Formal analysis, Writing – original draft. YS: Investigation, Writing – original draft. JT: Formal analysis, Writing – original draft. XL: Investigation, Writing – original draft. SJ: Writing – review & editing.

References

1. Jiang L, Lee CY, Sloan DA, Randle RW. Variation in the quality of thyroid nodule evaluations before surgical referral. *J Surg Res.* (2019) 244:9–14. doi: 10.1016/ j.jss.2019.06.024

2. Orloff LA, Noel JE, Stack BC, MD R, Angelos P, JH B, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benigm and Malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. *Head Neck*. (2022) 44:633–60. doi: 10.1002/hed.26960

3. Papini E, Monpeyssen H, Frasoldati A, Hegedüs L. European thyroid association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules. *Eur Thyroid J.* (2020) 9:172–85. doi: 10.1159/000508484

4. Xia B, Yu B, Wang X, Ma Y, Liu F, Gong Y, et al. Conspicuousness and recurrence related factors of ultrasound-guided microwave ablation in the treatment of benign thyroid nodules. *BMC Surg.* (2021) 21:317. doi: 10.1186/s12893-021-01312-1

5. Luo F, Huang L, Gong X, Han Z, Liu F, Cheng Z, et al. Microwave ablation of benign thyroid nodules: 3-year follow-up outcomes. *Head Neck*. (2021) 43:437–3447. doi: 10.1002/hed.26842

6. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous ultrasoundguided laser ablation of benign thyroid nodules: results of 10-year follow-up in 171 patients. *Endocr Soc.* (2021) 5:bvab081. doi: 10.1210/jendso/bvab081

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Acknowledgments

We would like to thank all participants for their support in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

7. Liu LH, Yang BB, Liu Y, Wang JL, Wang DD, Ding HY, et al. Factors related to the absorption rate of benign thyroid nodules after image-guided microwave ablation: a 3-year follow-up. *Int J Hyperther.* (2022) 39:8–14. doi: 10.1080/02656736.2021.1995632

8. Cappelli C, Franco F, Pirola I, Gandossi E, Marini F, Di Lodovico E, et al. Radiofrequency ablation of functioning and non-functioning thyroid nodules: a single institution 12-month survey. J Endocrinol Invest. (2020) 43:477–82. doi: 10.1007/s40618-019-01132-4

9. Cesareo R, Manfrini S, Pasqualini V, Ambrogi C, Sanson G, Gallo A, et al. Laser ablation versus radiofrequency ablation for thyroid nodules: 12-month results of a randomized trial (LARA II Study). *J Clin Endocr Metab.* (2021) 106:1692–701. doi: 10.1210/clinem/dgab102

10. Deandrea M, Garino F, Alberto M, Garberoglio R, Rossetto R, Bonelli N, et al. Radiofrequency ablation for benign thyroid nodules according to different ultrasound features: an Italian multicentre prospective study. *Eur J Endocr.* (2019) 180:79–87. doi: 10.1530/EJE-18-0685

11. Fu QQ, Kang S, Wu CP, Wang SY, Liu YY, Tian JW, et al. A study on the efficacy of microwave ablation for benign thyroid nodules and related influencing factors. *Int J Hyperther.* (2021) 38:1469–75. doi: 10.1080/02656736.2021.1988151

12. Li Y, He H, Li W, Zhao J, Ge N, Zhang Y, et al. Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up. *BMC Med Imag.* (2022) 22:75. doi: 10.1186/s12880-022-00795-5

13. Wang B, Han ZY, Yu J, Cheng Z, Liu F, Yu XL, et al. Factors related to recurrence of the benign non-functioning thyroid nodules after percutaneous microwave ablation. *Int J Hyperther.* (2017) 33:459–64. doi: 10.1080/02656736.2016.1274058

14. Fei Y, Qiu Y, Huang D, Xing Z, Li Z, Su A, et al. Effects of energy-based ablation on thyroid function in treating benign thyroid nodules: a systematic review and metaanalysis. *Int J Hyperther*. (2020) 37:1090–102. doi: 10.1080/02656736.2020.1806362

15. Squarcia M, Mora M, Aranda G, Carrero E, Martínez D, Jerez R, et al. Long-term follow-up of single-fiber multiple low-intensity energy laser ablation technique of benign thyroid nodules. *Front Oncol.* (2021) 11:584265. doi: 10.3389/fonc.2021.584265

16. Trimboli P, Deandrea M. Treating thyroid nodules by radiofrequency: is the delivered energy correlated with the volume reduction rate? A pilot study. *Endocrine.* (2020) 69:682–7. doi: 10.1007/s12020-02275-8

17. Gambelunghe G, Fede R, Bini V, Monacelli M, Avenia N, D'Ajello M, et al. Ultrasound-guided interstitial laser ablation for thyroid nodules is effective only at high total amounts of energy: results from a three-year pilot study. *Surg Innov.* (2013) 20:345–50. doi: 10.1177/1553350612459276

18. Amabile G, Rotondi M, Chiara GD, Silvestri A, Filippo BD, Bellastella A, et al. Low-energy interstitial laser photocoagulation for treatment of nonfunctioning thyroid nodules: therapeutic outcome in relation to pretreatment and treatment parameters. *Thyroid.* (2006) 16:749–55. doi: 10.1089/thy.2006.16.749

19. Han ZY, Dou JP, Zheng L, Xu M, Ren J, Wang H, et al. Chinese guidelines for ultrasound-guided thermal ablation of thyroid nodules (2024 edition). *Int J Surg.* (2025) 111:1699–710. doi: 10.1097/JS9.00000000002209

20. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The diagnosis and management of thyroid nodules: A review. *JAMA*. (2018) 319:914–24. doi: 10.1001/jama.2018.0898

21. Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. *Radiology.* (2000) 217:673–7. doi: 10.1148/radiology.217.3.r00dc09673

22. Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. *Thyroid*. (2006) 16:361–7. doi: 10.1089/ thy.2006.16.361

23. Feng B, Liang P, Cheng Z, Yu X, Yu J, Han Z, et al. Ultrasound-guided percutaneous microwave ablation of benign thyroid nodules: experimental and clinical studies. *Eur J Endocr.* (2012) 166:1031–7. doi: 10.1530/EJE-11-0966

24. Sengul I, Sengul D. Hermeneutics for evaluation of the diagnostic value of ultrasound elastography in TIRADS 4 categories of thyroid nodules. *Am J Med Case Rep.* (2021) 9:538–9. doi: 10.12691/ajmcr-9-11-5

25. Sengul D, Sengul I. Reassessing combining real-time elastography with fineneedle aspiration biopsy to identify Malignant thyroid nodules. *Am J Med Case Rep.* (2021) 9:552–3. doi: 10.12691/ajmcr-9-11-9 26. Sengul D, Sengul I. Association between Tsukuba elasticity scores 4 and 5 on elastography and Bethesda undetermined cytology on US-guided FNA with 27-G needle, verified by histopathology: a cut-off point of 20 mm of diameter designated for thyroid nodules. *J Buon.* (2019) 24:382–90.

27. Dobnig H, Amrein K. Monopolar radiofrequency ablation of thyroid nodules: a prospective Austrian single-center study. *Thyroid.* (2018) 28:472–80. doi: 10.1089/ thy.2017.0547

28. Holmer C, Lehmann KS, Knappe V, Zurbuchen U, Frericks B, Schumann T, et al. Bipolar radiofrequency ablation for nodular thyroid disease–ex vivo and *in vivo* evaluation of a dose-response relationship. *J Surg Res.* (2011) 169:234–40. doi: 10.1016/j.jss.2009.10.009

29. Cao S, Wang L, Wei Y, Zhao Z, Wu J, Yu M. Influence factors and nomogram for volume reduction rate in benign thyroid nodule after thermal ablation. *Int J Hyperther.* (2023) 40:2220562. doi: 10.1080/02656736.2023.2220562

30. Kim JH, Na DG, Lee H. Ultrasonographic echogenicity and histopathologic correlation of thyroid nodules in core needle biopsy specimens. *Korean J Radiol.* (2018) 19:673–81. doi: 10.3348/kjr.2018.19.4.673

31. He H, Zhang Y, Song Q, Zhao J, Li W, Li Y, et al. Nomogram prediction for the involution of the ablation zone after radiofrequency ablation treatment in patients with low-risk papillary thyroid carcinoma. *Int J Hyperther.* (2021) 38:1133–9. doi: 10.1080/02656736.2021.1960434

32. Deandrea M, Trimboli P, Mormile A, Cont AT, Milan L, Buffet C, et al. Determining an energy threshold for optimal volume reduction of benign thyroid nodules treated by radiofrequency ablation. *Eur Radiol.* (2021) 31:5189–97. doi: 10.1007/s00330-020-07532-y

33. Korkusuz Y, Kohlhase K, Gröner D, Erbelding C, Luboldt W, Happel C, et al. Microwave ablation of symptomatic benign thyroid nodules: Energy requirement per ml volume reduction. *RoFo.* (2016) 188:1054–60. doi: 10.1055/s-0042-115416

34. Klebe J, Happel C, Grünwald F, Korkusuz H. Visualization of tissue alterations in thyroid nodules after microwave ablation: sonographic versus scintigraphic imaging. *Nucl Med Commun.* (2015) 36:260–7. doi: 10.1097/MNM.0000000000242

35. Yue WW, Wang SR, Lu F, Sun LP, Guo LH, Zhang YL, et al. Radiofrequency ablation vs. *microwave ablation patients benign Thyroid nodules: propensity score matching study. Endocrine.* (2017) 55:485–95. doi: 10.1007/s12020-016-1173-5

36. Spartalis E, Karagiannis SP, Plakopitis N, Theodori MA, Athanasiadis DI, Schizas D, et al. Percutaneous laser ablation of cervical metastatic lymph nodes in papillary thyroid carcinoma: clinical efficacy and anatomical considerations. *Expert Rev Med Devic*. (2021) 18:75–82. doi: 10.1080/17434440.2021.1864323